SAN DIEGO--(BUSINESS WIRE)--ASCB 2009 – PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced the expansion of its “No Wash” ALPHA (Amplified Luminescent Proximity Homogeneous Assay) Technology portfolio by introducing 46 new highly sensitive cell signaling pathway and biomarker research assay kits. The new assays provide researchers with comprehensive tools for advancing studies in cancer, inflammatory, and neurodegenerative disorders.
PerkinElmer’s AlphaScreen®SureFire® assays enable researchers to save time by providing the ability to study key biological pathways using the same sample and conditions in a single experiment. In addition, the kits simplify complex protocols, increasing the ability to automate high-throughput screening processes and assisting researchers in the transition from time-consuming Western Blot or ELISA methods.
In addition, the Company’s AlphaLISA® “No Wash” immunoassay kits enable the study of biomarkers for multiple disease states. The latest assays include human and mouse biomarker targets, significantly broadening the applicability of the ELISA-alternative ALPHA technology portfolio.
“PerkinElmer continues to make great strides with the expansion of the ALPHA Technology portfolio, based on scientific demand for alternative ways to measure cell signaling pathways and biomarkers,” said Richard M. Eglen, PhD, president, Bio-discovery, PerkinElmer. “The new kits will help open new directions in research for diseases such as cancer, Alzheimer’s, cardiovascular and inflammatory conditions.”
The 46 new offerings include 22 AlphaScreen®SureFire® and 24 AlphaLISA® “No Wash” immunoassay kits, bringing the combined number of ALPHA-based kits to 142 assays (66 AlphaScreen SureFire and 76 AlphaLISA assays).
PerkinElmer’s ALPHA Technology is a powerful, proprietary bead-based platform that allows highly sensitive detection of biomolecules and biomolecular interactions, while removing unwieldy wash steps, eliminating labor intensive processes that are difficult to automate. It allows researchers to overcome traditional limitations for ELISA and Western Blotting, enabling savings in time, precious samples and antibody usage. ALPHA Technology is easy to miniaturize and automate, also enabling an efficient high-throughput screening setup.
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2 billion in 2008, has around 8,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
SureFire® is a registered trademark of TGR BioSciences Pty Ltd.
Contact:
PerkinElmer, Inc. Kim McCrossen, 781-663-5871 kim.mccrossen@perkinelmer.com
